Nearly 40 pharmaceutical companies disclosed their performance in the first quarter of 2022, with a high pre-happy rate

Recently, the first quarter performance forecast of listed companies in 2022 has begun to surface one after another
.
According to industry statistics, as of April 13, a total of 38 pharmaceutical companies have disclosed their performance in the first quarter, and more than 80% of the companies are happy
.
Among them, Kangyuan Pharmaceutical is the first pharmaceutical company to disclose the first quarterly report, and has achieved double growth in net profit and revenue, which will be realized in the first quarter of 2022
.
On April 14, another group of pharmaceutical companies issued a first-quarter performance pre-announcement, including Guoxin Health, Yongan Pharmaceutical, and Mingde Bio
.
Guoxin Health: Loss reduction Guoxin Health expects to realize a net profit loss of about 49.
4 million yuan in the first quarter of this year, compared with a loss of 56.
26 million yuan in the same period last year, the year-on-year loss has decreased, and the basic earnings per share is about -0.
0545 yuan
.
The company's business as a whole shows seasonal characteristics of low before and high, and the overall operating conditions continue to improve.
During the reporting period, the operating income increased by about 10 million yuan year-on-year, with a growth rate of about 38%, mainly due to the year-on-year increase in digital medical insurance revenue; the company's total operating costs were year-on-year.
The growth rate is about 14%, and the operating loss has narrowed
.
According to the data, Guoxin Health is a medical and health security service company.
Its main products include pharmaceutical e-commerce, digital entertainment, high-tech chemical fiber and other businesses
.
During the reporting period, in accordance with the development goals and business directions determined by the strategic plan, the company closely focused on the national strategy of "Healthy China" and the reform requirements of "three medical linkages", with digital medical insurance as the main body, and digital medical care and digital medicine as the two wings to build a basic plan.
, focusing on the three major business directions of medical insurance fund comprehensive management services, medical quality and safety services, and drug device supervision services, constantly promoting mechanism innovation, digging in-depth data value, actively carrying out investment cooperation, and creating a closed loop of digital + medical + insurance + medicine
.
Yongan Pharmaceutical: Net profit increased by 520.
00%-570.
00% year-on-year Yongan Pharmaceutical expects to achieve a net profit of 48.
6343 million yuan to 52.
5564 million yuan from January 1, 2022 to March 31, 2022, an increase of 520.
00% to 570.
00% , the basic earnings per share is 0.
1650 yuan to 0.
1783 yuan
.
The main reasons for the company's expected performance in the first quarter of 2022 to increase significantly year-on-year are: first, during the reporting period, the company's main product taurine was in strong market demand, and the sales price rose significantly compared with the same period last year; second, due to the ownership of the first quarter of 2021.
The net profit base of shareholders of listed companies is relatively low, and the performance in the first quarter of 2022 has increased significantly compared with that of the first quarter of 2022
.
According to the data, Yongan Pharmaceutical and its subsidiaries are mainly engaged in four types of business, one is the research and development, production and sales of taurine products; R&D, production and sales of water preparations and other related products; 3.
R&D, production and sales of health food and import and sales of foreign health food; 4.
Equity or industrial investment related to the health field, and use of some idle funds for cash management,
etc.
Mingde Bio: Net profit increased by 295.
61%-324.
91% year-on-year According to the first quarter performance forecast released by Mingde Bio, the net profit attributable to shareholders of listed companies in the first quarter of 2022 is expected to be 1.
35 billion yuan to 1.
45 billion yuan, a year-on-year increase of 295.
61%- 324.
91%; basic earnings per share are about 12.
87 yuan -13.
83 yuan
.
There are three main reasons for the change in performance: first, the epidemic has led to an increase in the demand for nucleic acid detection reagents, the company's nucleic acid detection reagent market share continues to rise, and nucleic acid detection reagents and services related revenue has increased significantly; second, in March 2022, China decided to On the basis of nucleic acid detection, antigen detection is added as a supplement
.
On March 15, 2022, the company newly approved antigen detection kits in China and successively won bids in many provinces across the country.
Shanghai, Jilin, Shandong and other places have increased the demand for the company's antigen detection kits and brought related product operations.
The increase in performance; thirdly, the demand for antigen detection kits in overseas markets has increased, and the company's export orders have increased significantly year-on-year
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.